MA35110B1 - Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae - Google Patents

Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae

Info

Publication number
MA35110B1
MA35110B1 MA36409A MA36409A MA35110B1 MA 35110 B1 MA35110 B1 MA 35110B1 MA 36409 A MA36409 A MA 36409A MA 36409 A MA36409 A MA 36409A MA 35110 B1 MA35110 B1 MA 35110B1
Authority
MA
Morocco
Prior art keywords
pilin
fusion proteins
haemophilus influenzae
polyvaccines
including protein
Prior art date
Application number
MA36409A
Other languages
English (en)
Inventor
Normand Blais
Steve Labbe
Jan Poolman
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47008755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35110(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA35110B1 publication Critical patent/MA35110B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des compositions comprenant la protéine e et la piline a d'haemophilus influenzae. Plus particulièrement, la présente demande concerne des protéines de fusion et des compositions immunogènes comprenant la protéine e et pila, des vaccins contenant ces compositions immunogènes et leurs utilisations thérapeutiques.
MA36409A 2011-04-13 2013-11-08 Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae MA35110B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474779P 2011-04-13 2011-04-13
US201161534012P 2011-09-13 2011-09-13
PCT/CA2012/050236 WO2012139225A1 (fr) 2011-04-13 2012-04-12 Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae

Publications (1)

Publication Number Publication Date
MA35110B1 true MA35110B1 (fr) 2014-05-02

Family

ID=47008755

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36409A MA35110B1 (fr) 2011-04-13 2013-11-08 Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae

Country Status (36)

Country Link
US (7) US8945577B2 (fr)
EP (2) EP2707393B1 (fr)
JP (1) JP6196963B2 (fr)
KR (1) KR101999673B1 (fr)
CN (3) CN103476799A (fr)
AR (1) AR086078A1 (fr)
AU (1) AU2012243412C1 (fr)
BR (1) BR112013026175B1 (fr)
CA (1) CA2830786C (fr)
CL (1) CL2013002937A1 (fr)
CO (1) CO6781540A2 (fr)
CR (1) CR20130529A (fr)
CY (2) CY1120319T1 (fr)
DK (2) DK3321287T3 (fr)
DO (1) DOP2013000235A (fr)
EA (1) EA031580B1 (fr)
ES (2) ES2658512T3 (fr)
HR (2) HRP20180216T1 (fr)
HU (2) HUE048848T2 (fr)
IL (2) IL271862B (fr)
LT (2) LT3321287T (fr)
MA (1) MA35110B1 (fr)
ME (1) ME02995B (fr)
MX (1) MX350013B (fr)
PE (1) PE20140986A1 (fr)
PH (1) PH12013502121A1 (fr)
PL (2) PL2707393T3 (fr)
PT (2) PT3321287T (fr)
RS (1) RS56903B1 (fr)
SG (2) SG10201602549WA (fr)
SI (2) SI2707393T1 (fr)
SM (1) SMT201800125T1 (fr)
TW (1) TW201302779A (fr)
UY (1) UY34017A (fr)
WO (1) WO2012139225A1 (fr)
ZA (1) ZA201307118B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
BR112015008418A2 (pt) * 2012-10-17 2017-07-04 Glaxosmithkline Biologicals Sa uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
CA2961967C (fr) 2013-09-30 2023-10-03 Island Abbey Foods Ltd. Produit a macher et son procede de production
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
US10648966B2 (en) * 2015-01-16 2020-05-12 University Of Kentucky Research Foundation Lipid bilayer-integrated SPP1 connector protein nanopore and SPP1 connector protein variants for use as lipid bilayer-integrated nanopore
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
JP2020515587A (ja) * 2017-03-31 2020-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 免疫原性組成物、使用及び処置方法
WO2018178265A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et procédé de traitement
CA3063954A1 (fr) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Procedes de fabrication d'un adjuvant
EP3641808A1 (fr) * 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Procédés d'amplification des réponses immunitaires
CN107602697B (zh) * 2017-08-29 2020-05-05 杭州医学院 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN112703006A (zh) * 2018-06-19 2021-04-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CN112601545A (zh) 2018-08-07 2021-04-02 葛兰素史密丝克莱恩生物有限公司 工艺和疫苗
US12551553B2 (en) 2018-11-29 2026-02-17 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN110540598B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法
CN110540597B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法
EP3931206A1 (fr) 2019-02-27 2022-01-05 Evaxion Biotech ApS Vaccins ciblant h. influenzae
EP3956666A1 (fr) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Protéines de liaison à l'antigène et dosages
EP3980044A1 (fr) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Purification de saponine
EP4009951A1 (fr) * 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Procédé de préparation d'une composition comprenant un polypeptide de protéine d
MX2022001488A (es) * 2019-08-05 2022-03-02 Glaxosmithkline Biologicals Sa Composicion inmunogenica.
EP4294433A1 (fr) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Composition immunogène, utilisation et procédés
KR20220142219A (ko) * 2021-04-14 2022-10-21 한국생명공학연구원 장내 미생물에서 단백질 분비를 유도하는 신호서열
EP4558170A1 (fr) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Procédé continu de production de vaccin

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0462210B1 (fr) * 1989-03-09 1994-09-07 Praxis Biologics, Inc. Vaccins contre les haemophilus influenzae inclassifiables
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
JP4028593B2 (ja) 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
IL122588A (en) 1995-06-23 2001-12-23 Smithkline Beecham Biolog A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
AU746442B2 (en) 1996-12-20 2002-05-02 Board Of Regents, The University Of Texas System UspA1 and UspA2 antigens of Moraxella catarrhalis
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
ES2435923T3 (es) 2000-10-02 2013-12-26 Id Biomedical Corporation Of Quebec Antígenos de Haemophilus influenzae y los correspondientes fragmentos de ADN
AU2002258734A1 (en) 2001-04-13 2002-10-28 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
WO2003035836A2 (fr) 2001-10-24 2003-05-01 Hybridon Inc. Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5'
GB0222764D0 (en) 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide
US7049076B2 (en) 2003-07-09 2006-05-23 Sentigen Biosciences, Inc. Method for assaying protein—protein interaction
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
CN101175856A (zh) * 2005-05-12 2008-05-07 诺瓦提斯公司 猪痢疾短螺旋体的基因和蛋白质及其用于诊断和治疗的用途
ES2335136T3 (es) 2005-07-08 2010-03-22 University Of Zurich Expresion fagica mediante translocacion cotraduccional de polipeptidos de fusion.
US7811591B2 (en) * 2005-07-08 2010-10-12 Nationwide Children's Hospital, Inc. Chimeric vaccine for haemophilus influenzae-induced disease
EP2548885B1 (fr) 2005-08-10 2017-10-18 Arne Forsgren AB Interaction de moraxella catarrhalis avec des cellules épithéliales, des protéines matricielles extracellulaires et le système compleméntaire
ES2809167T3 (es) * 2006-01-17 2021-03-03 Forsgren Arne Una novedosa proteína de Haemophilus influenzae expuesta en la superficie (proteína E; pE)
GB2444903A (en) * 2006-12-21 2008-06-25 Secr Defence Live Francisella vaccine, inactivated at gene FTT1564
EP2319869B1 (fr) 2008-06-20 2016-08-17 National University Corporation Okayama University ANTICORPS CONTRE UN COMPLEXE LDL/ß²GPT OXIDÉ ET SON UTILISATION
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗

Also Published As

Publication number Publication date
EA201391240A1 (ru) 2014-04-30
EP3321287B1 (fr) 2020-02-26
US10214569B2 (en) 2019-02-26
CN107383201A (zh) 2017-11-24
EP3321287A1 (fr) 2018-05-16
US20200331972A1 (en) 2020-10-22
JP6196963B2 (ja) 2017-09-13
SG193906A1 (en) 2013-11-29
KR20140026483A (ko) 2014-03-05
US8945577B2 (en) 2015-02-03
ES2658512T3 (es) 2018-03-12
US11198707B2 (en) 2021-12-14
CA2830786A1 (fr) 2012-10-18
CY1122824T1 (el) 2021-05-05
DOP2013000235A (es) 2014-03-16
AR086078A1 (es) 2013-11-20
BR112013026175A2 (pt) 2016-11-29
PT2707393T (pt) 2018-02-09
PH12013502121A1 (en) 2014-01-13
MX2013011939A (es) 2014-03-27
IL228344A0 (en) 2013-12-31
ME02995B (fr) 2018-10-20
AU2012243412B2 (en) 2015-05-14
IL271862A (en) 2020-02-27
ES2776369T3 (es) 2020-07-30
HUE036983T2 (hu) 2018-08-28
US10730917B2 (en) 2020-08-04
US20170029472A1 (en) 2017-02-02
DK3321287T3 (da) 2020-05-04
US20180222946A1 (en) 2018-08-09
IL228344B (en) 2020-01-30
US9296794B2 (en) 2016-03-29
EP2707393A4 (fr) 2014-11-05
CR20130529A (es) 2014-03-05
JP2014512365A (ja) 2014-05-22
EA031580B1 (ru) 2019-01-31
AU2012243412C1 (en) 2015-12-10
SI3321287T1 (sl) 2020-07-31
BR112013026175B1 (pt) 2020-05-12
MX350013B (es) 2017-08-23
US20160250313A1 (en) 2016-09-01
WO2012139225A1 (fr) 2012-10-18
CA2830786C (fr) 2021-10-26
SI2707393T1 (en) 2018-03-30
HRP20180216T1 (hr) 2018-03-09
EP2707393A1 (fr) 2014-03-19
CL2013002937A1 (es) 2014-07-25
TW201302779A (zh) 2013-01-16
ZA201307118B (en) 2022-03-30
PE20140986A1 (es) 2014-08-20
CN103476799A (zh) 2013-12-25
CY1120319T1 (el) 2019-07-10
AU2012243412A1 (en) 2013-04-18
HRP20200466T1 (hr) 2020-06-26
CO6781540A2 (es) 2013-10-31
PL3321287T3 (pl) 2020-07-27
NZ615328A (en) 2015-10-30
LT2707393T (lt) 2018-03-12
RS56903B1 (sr) 2018-05-31
US20150166613A1 (en) 2015-06-18
US20150175670A1 (en) 2015-06-25
DK2707393T3 (da) 2018-01-29
SG10201602549WA (en) 2016-05-30
EP2707393B1 (fr) 2017-12-20
HUE048848T2 (hu) 2020-08-28
LT3321287T (lt) 2020-06-10
PL2707393T3 (pl) 2018-05-30
PT3321287T (pt) 2020-05-22
IL271862B (en) 2022-07-01
SMT201800125T1 (it) 2018-05-02
UY34017A (es) 2012-11-30
US20140056934A1 (en) 2014-02-27
US10023616B2 (en) 2018-07-17
CN107522788A (zh) 2017-12-29
US9409957B2 (en) 2016-08-09
KR101999673B1 (ko) 2019-07-12

Similar Documents

Publication Publication Date Title
MA35110B1 (fr) Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae
EA201590705A1 (ru) ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ
PE20142115A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
IN2012DN02736A (fr)
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1118601T1 (el) Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
UA104005C2 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201001639A1 (ru) Композиции и способы их получения и применения
MX360448B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
EA201590490A1 (ru) ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ОДИН ИЛИ БОЛЕЕ КОНЪЮГАТОВ КАПСУЛЬНЫХ САХАРИДОВ STREPTOCOCCUS PNEUMONIAE И БЕЛКОВЫЙ КОМПОНЕНТ, ВКЛЮЧАЮЩИЙ БЕЛОК Е И/ИЛИ PilA ИЗ HAEMOPHILIUS INFLUENZAE
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
PH12013500143A1 (en) A method of treating alzheimer`s disease
EA201400827A1 (ru) Материалы и способы лечения диареи
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
EA201590752A1 (ru) Препараты производных пиримидиндиона
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EP2566508A4 (fr) Conjugaison de polysaccharide à une entérotoxine thermolabile (lt) d'e.coli détoxifiée, utilisée comme vaccin
MX2015009141A (es) Formulaciones de albu-bche, preparacion y usos de las mismas.